Digoxin Use and Associated Adverse Events Among Older Adults.

[1]  Deepak L. Bhatt,et al.  Temporal Trends of Digoxin Use in Patients Hospitalized With Heart Failure: Analysis From the American Heart Association Get With The Guidelines-Heart Failure Registry. , 2016, JACC. Heart failure.

[2]  E. Lewis,et al.  Digoxin Toxicity and Use of Digoxin Immune Fab: Insights From a National Hospital Database. , 2016, JACC. Heart failure.

[3]  M. Ezekowitz,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.

[4]  M. Ezekowitz,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.

[5]  M. Turakhia,et al.  Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. , 2014, Journal of the American College of Cardiology.

[6]  Nadine Shehab,et al.  Emergency Department Visits and Hospitalizations for Digoxin Toxicity: United States, 2005 to 2010 , 2014, Circulation. Heart failure.

[7]  A. Go,et al.  Effectiveness and Safety of Digoxin Among Contemporary Adults With Incident Systolic Heart Failure , 2013, Circulation. Cardiovascular quality and outcomes.

[8]  T. N. Harrison,et al.  Digoxin and Risk of Death in Adults With Atrial Fibrillation: The ATRIA-CVRN Study , 2013, Circulation. Arrhythmia and electrophysiology.

[9]  A. Goldberger,et al.  Therapeutic ranges of serum digoxin concentrations in patients with heart failure. , 2012, The American journal of cardiology.

[10]  H. Leu,et al.  Exposure to sennoside–digoxin interaction and risk of digoxin toxicity: a population‐based nested case–control study † , 2011, European journal of heart failure.

[11]  H. Leu,et al.  Risk of digoxin intoxication in heart failure patients exposed to digoxin-diuretic interactions: a population-based study. , 2010, British journal of clinical pharmacology.

[12]  J. Cohn,et al.  Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT). , 2010, Congestive heart failure.

[13]  Meng-Ting Wang,et al.  Risk of digoxin intoxication caused by clarithromycin–digoxin interactions in heart failure patients: a population-based study , 2009, European Journal of Clinical Pharmacology.

[14]  J. Butler,et al.  Digoxin Therapy Does Not Improve Outcomes in Patients With Advanced Heart Failure on Contemporary Medical Therapy , 2009, Circulation. Heart failure.

[15]  Sharon-Lise T. Normand,et al.  An Administrative Claims Measure Suitable for Profiling Hospital Performance on the Basis of 30-Day All-Cause Readmission Rates Among Patients With Heart Failure , 2008, Circulation. Cardiovascular quality and outcomes.

[16]  S. Hennessy,et al.  Declining Public Health Burden of Digoxin Toxicity From 1991 to 2004 , 2008, Clinical pharmacology and therapeutics.

[17]  Harold I Feldman,et al.  Diagnostic E-codes for commonly used, narrow therapeutic index medications poorly predict adverse drug events. , 2008, Journal of clinical epidemiology.

[18]  P. Hauptman,et al.  Digoxin use and digoxin toxicity in the post-DIG trial era. , 2006, Journal of cardiac failure.

[19]  S. Normand,et al.  An Administrative Claims Model Suitable for Profiling Hospital Performance Based on 30-Day Mortality Rates Among Patients With an Acute Myocardial Infarction , 2006, Circulation.

[20]  Harlan M Krumholz,et al.  An Administrative Claims Model Suitable for Profiling Hospital Performance Based on 30-Day Mortality Rates Among Patients With Heart Failure , 2006, Circulation.

[21]  A. Laupacis,et al.  Drug-drug interactions among elderly patients hospitalized for drug toxicity. , 2003, JAMA.

[22]  Harlan M Krumholz,et al.  Association of serum digoxin concentration and outcomes in patients with heart failure. , 2003, JAMA.

[23]  Harlan M Krumholz,et al.  Sex-based differences in the effect of digoxin for the treatment of heart failure. , 2002, The New England journal of medicine.

[24]  E. Hazan,et al.  Relationship between high serum digoxin levels and toxicity. , 1997, International journal of clinical pharmacology and therapeutics.

[25]  E. J. Brown,et al.  The effect of digoxin on mortality and morbidity in patients with heart failure. , 1997, The New England journal of medicine.

[26]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[27]  S. Yusuf,et al.  Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure , 1995 .

[28]  P. Poole‐Wilson,et al.  Diuretics for heart failure. , 2012, The Cochrane database of systematic reviews.

[29]  A. Laupacis,et al.  A population-based assessment of the potential interaction between serotonin-specific reuptake inhibitors and digoxin. , 2005, British journal of clinical pharmacology.